Literature DB >> 7575715

A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis.

A E Clarke1, D A Bloch, T A Medsger, C V Oddis.   

Abstract

OBJECTIVE: To analyze changes in functional status and the factors contributing to disability in a national inception cohort of 257 patients with polymyositis/dermatomyositis (PM/DM).
METHODS: Data were gathered from patients' self-reports on questionnaires: one concerning disease- and treatment-related complications, and the other concerning disability, as reflected by a disability index (DI) derived from the Health Assessment Questionnaire (HAQ).
RESULTS: Based on certain characteristics that differentiated disability patterns, 3 groups of patients were identified. Group 1 patients (n = 153) were < or = 60 years old and never had avascular necrosis (AVN) or a vertebral compression fracture (CF), Group 2 patients were > 60 and never had AVN or a vertebral CF, and Group 3 patients reported AVN or a vertebral CF irrespective of age. As measured by the HAQ DI, disability increased very gradually over time in Group 1 patients and more rapidly in Group 2 and Group 3 patients. The increase in disability in patients experiencing AVN was greater than that in patients with similar pre-AVN disease characteristics who did not develop AVN (P = 0.003).
CONCLUSION: In this prospective study of disease course and iatrogenic factors related to functional disability in PM/DM, the HAQ DI increased with disease duration. Corticosteroid-related morbidity, as reflected by the development of AVN or CF, significantly contributed to patient-reported functional disability.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575715     DOI: 10.1002/art.1780380907

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

Review 1.  The benefits and limitations of a physical training program in patients with inflammatory myositis.

Authors:  M Lawson Mahowald
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 2.  Exercise: an important component of treatment in the idiopathic inflammatory myopathies.

Authors:  Helene Alexanderson
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 3.  Implications of glucocorticoid therapy in idiopathic inflammatory myopathies.

Authors:  Beatriz Y Hanaoka; Charlotte A Peterson; Craig Horbinski; Leslie J Crofford
Journal:  Nat Rev Rheumatol       Date:  2012-06-12       Impact factor: 20.543

4.  Physical impairment in patients with idiopathic inflammatory myopathies is associated with the American College of Rheumatology functional status measure.

Authors:  Beatriz Y Hanaoka; Laura C Cleary; Douglas E Long; Archana Srinivas; Kirk A Jenkins; Heather M Bush; Catherine P Starnes; Mathew Rutledge; Jidan Duan; Qian Fan; Natasha Fraser; Leslie J Crofford
Journal:  Clin Rheumatol       Date:  2014-11-12       Impact factor: 2.980

Review 5.  Juvenile dermatomyositis: recognition and treatment.

Authors:  Ann M Reed; Maricarmen Lopez
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 6.  Morbidity and mortality in adult polymyositis and dermatomyositis.

Authors:  Isabelle Marie
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 7.  [Patient-centered assessment of functional health in systemic sclerosis -- where are we now?].

Authors:  T Sigl; T Ewert; G Stucki
Journal:  Z Rheumatol       Date:  2004-12       Impact factor: 1.372

8.  The long-term outcome of anti-Jo-1-positive inflammatory myopathies.

Authors:  Michael Späth; Mira Schröder; Beate Schlotter-Weigel; Maggie C Walter; Hubert Hautmann; Gerda Leinsinger; Dieter Pongratz; Wolfgang Müller-Felber
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

9.  Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up.

Authors:  K P Ng; F Ramos; S M Sultan; D A Isenberg
Journal:  Clin Rheumatol       Date:  2009-04-23       Impact factor: 2.980

Review 10.  The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy.

Authors:  Shabina M Sultan
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.